Diana Ernst, RPh

Editorial Director

Diana Ernst, RPh, is the Editorial Director for MPR, part of the Haymarket Medical Network. Since 2003, Diana has worked to provide healthcare professionals with up-to-date drug information through MPR's print and digital offerings. She is a graduate of the Ernest Mario School of Pharmacy, Rutgers University.

All articles by Diana Ernst, RPh

COVID19

Study to Assess Antiviral Antibody Cocktail for COVID-19 Prevention Begins

Diana Ernst, RPh

July 9, 2020

A phase 3 trial evaluating an investigational antiviral antibody cocktail, REGN-COV2, for the prevention of COVID-19 has been initiated by Regeneron Pharmaceuticals.

COVID19

NIH: Trial Investigating Hydroxychloroquine for COVID-19 Stopped

Diana Ernst, RPh

June 26, 2020

A National Institutes of Health-led clinical trial evaluating hydroxychloroquine for the treatment of coronavirus disease 2019 (COVID-19) has been halted after a data and safety monitoring board determined that the drug was unlikely to benefit hospitalized patients.

COVID19

FDA: Coadministration of Remdesivir With CQ or HCQ Not Recommended

Diana Ernst, RPh

June 22, 2020

The antiviral activity of remdesivir, an investigational treatment for COVID-19, may potentially be reduced if it is coadministered with chloroquine or hydroxychloroquine, according to the FDA.

COVID19

FDA: Emergency Use Authorization Revoked for Chloroquine, Hydroxychloroquine

Diana Ernst, RPh

June 19, 2020

The FDA has revoked the emergency use authorization for chloroquine phosphate and hydroxychloroquine sulfate based on emerging data suggesting that these agents are unlikely to be effective against COVID-19.

COVID19

Early Data Show Potential Benefit of Acalabrutinib in Severe COVID-19

Diana Ernst, RPh

June 12, 2020

Acalabrutinib, a Bruton tyrosine kinase (BTK) inhibitor, appears to reduce respiratory distress as well as the hyperinflammatory immune response associated with coronavirus disease 2019.

Dutrebis (lamivudine and raltegravir tablets; Merck) was approved for the treatment of HIV-1 infection in patients aged ≥6 years old weighing ≥30kg, in combination with other antiretrovirals.

COVID19

Merck Collaborating on Novel COVID-19 Vaccine, Oral Antiviral

Diana Ernst, RPh

June 9, 2020

The vaccine candidate is currently in preclinical development with clinical studies expected to begin later this year.

COVID19

Pipeline: Immunotherapies and Other Investigational Therapies for COVID-19

Diana Ernst, RPh

May 15, 2020

While no specific treatment for coronavirus disease 2019 (COVID-19) is currently available, several therapies are being investigated globally.

COVID19

COVID-19 mRNA Vaccine Candidates Advancing Through the Pipeline

Diana Ernst, RPh

May 14, 2020

A phase 2 study of Moderna’s vaccine candidate for COVID-19, mRNA-1273, is expected to start shortly following the Food and Drug Administration’s review of the Company’s Investigational New Drug (IND) application.

COVID19

Pipeline: Investigational Vaccines for COVID-19

Diana Ernst, RPh

May 6, 2020

While no specific treatment for coronavirus disease 2019 (COVID-19) is currently available, several therapies are being investigated globally.

COVID19

FDA Urges Recovered COVID-19 Patients to Donate Plasma

Diana Ernst, RPh

April 21, 2020

The FDA has launched a new webpage with information for recovered individuals who were infected with coronavirus disease 2019 (COVID-19) on where they can go to donate plasma to aid in the treatment of severely ill patients.

Next post in COVID19